BMS drug Opdivo lands FDA approval for gastro cancers By Jenni Spinner The therapeutic has been approved as an adjuvant treatment for varieties of esophageal cancers in patients who have received neoadjuvant chemoradiotherapy.
Bristol Myers Squibb (BMS) announced the US Food and Drug Administration (FDAP has approved Opdivo (nivolumab, injection for intravenous use) for adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT). The approval is based upon results from the recent Phase III CheckMate -577 trial, which evaluated the drug in comparison to placebo in esophageal or GEJ cancer patients with residual pathologic disease following neoadjuvant CRT and complete resection.
Authorities are investigating after a coffin bearing the scrawled words “Diamond Ross” was found on the front lawn of Dallas County District Attorney John.
Care of Post-Acute COVID-19 Patients Requires Collaboration medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.